alexa Challenges From The New European Pharmacovigilance Legislation And Their Implementation By Competent Authorities
ISSN: 2329-6887

Journal of Pharmacovigilance
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd International Conference and Exhibition on Pharmacovigilance & Clinical Trials
November 18-19, 2013 Hilton San Antonio Airport, TX, USA

Walter Schwerdtfeger
KeyNote: J Pharmacovigilance
DOI: 10.4172/2329-6887.S1.006
Abstract
In July 2012, the new European Pharmacovigilance Legislation came into force, being the most important change to the regulation of human medicines in the European Union since 1995. The new legislation has significant implications for both the pharmaceutical industry and regulators. Within the European network roles and responsibilities have been made clearer, and one objective is to minimize duplication of efforts. However, the new legislation and its implementation also put a considerable surplus load on the European Medicines Agency and national competent authorities. Although decision-making has more and more been moving to the European level, a substantial part of the work, e.g. assessment of dossiers and scientific evaluation of data, still has to be performed by national authorities. The new tasks include strengthened requirements for risk management plans (RMP), a harmonized approach for signal detection and signal assessment within a clear legal framework, and increased transparency as well as communication to the public. Furthermore, once a new safety concern has been detected after approval of a medicine, the procedures for evaluating the data, agreeing on regulatory measures, and giving final recommendations have been enhanced and further harmonized. One of the main challenges for national authorities to deal with is the requirement to have an RMP in place for any new medicinal product being authorized, including generics, with only few exceptions. A summary of each RMP has to be published. With currently only having one-year of experience with these new requirements, careful evaluation of their long-term practicability will be needed in the future.
Biography
Walter Schwerdtfeger received his Science Ph.D. from Johann-Wolfgang-Goethe University in Frankfurt am Main. He continued his career at the Max-Planck-Institute for Brain Research and the Paul-Ehrlich-Institute, then he switched to the Federal Ministry of Health in Bonn. Since 2010, he is the President of the Federal Institute for Drugs and Medical Devices. He has been working as a lecturer and professor at the Universities of Frankfurt, Valencia (Spain) and Bonn, published in reputed journals and organized scientific symposia and workshops. He is Vice-Chair of the Management Board of the European Medicines Agency in London.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords